Drug Profile
Hydroxypropyl betadex - Mitsubishi Tanabe Pharma Corporation
Alternative Names: 2-hydroxypropyl betadex - Mitsubishi Tanabe Pharma Corporation; Beta hydroxypropylcyclodextrin - Mitsubishi Tanabe Pharma Corporation; HPBCD - Mitsubishi Tanabe Pharma Corporation; Hydroxypropyl beta cyclodextrin - Mitsubishi Tanabe Pharma CorporationLatest Information Update: 17 Apr 2018
Price :
$50
*
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Anti-inflammatories; Antidementias; Antivirals; Beta-Cyclodextrins; Ethers; Peripheral vasodilators; Urologics; Vascular disorder therapies
- Mechanism of Action Binding agents; Cholesterol modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Niemann-Pick diseases
Most Recent Events
- 17 Apr 2018 Discontinued - Clinical-Phase-Unknown for Niemann-Pick disease in Japan (Intrathecal)
- 28 Jan 2018 No recent reports of development identified for clinical-Phase-Unknown development in Niemann-Pick-disease in Japan (Intrathecal)